Biotech company Galapagos NV has announced a strategic shift in plans regarding its previously proposed corporate separation, alongside key changes to its executive leadership and Board of Directors.
In January 2025, Galapagos revealed its intention to split into two independent publicly listed companies – one focused on novel cell therapies and the other (SpinCo) on building a new drug pipeline through transformational deals.
However, due to evolving regulatory and market conditions, the company is now re-evaluating the separation and considering a range of strategic alternatives for its current businesses, including its cell therapy unit.
Effective immediately, the Galapagos Board of Directors has appointed Henry Gosebruch as CEO and Executive Director, succeeding Dr. Paul Stoffels, who announced his retirement in April. Gosebruch had previously been named the founding CEO of SpinCo and will now lead Galapagos through its strategic reassessment while seeking new growth opportunities.
In another leadership move, Jérôme Contamine, formerly Lead Non-Executive Director, has been named Chair of the Board, replacing Dr. Stoffels, who will continue to support the company in an advisory role during the review of its cell therapy programs.
Gosebruch emphasized a dual focus moving forward: evaluating potential mergers, divestitures, and out-licensing deals for existing assets – including Galapagos’ cell therapy program GLPG5101 – while pursuing transformative business development to build a new pipeline of innovative treatments.
These developments mark a new chapter for Galapagos as it aims to realign its strategy and leverage its strong financial position to deliver greater value for patients and shareholders alike.
